1. Home
  2. AMPG vs MGNX Comparison

AMPG vs MGNX Comparison

Compare AMPG & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amplitech Group Inc.

AMPG

Amplitech Group Inc.

HOLD

Current Price

$2.89

Market Cap

93.8M

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.56

Market Cap

94.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPG
MGNX
Founded
2002
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.8M
94.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
AMPG
MGNX
Price
$2.89
$1.56
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.20
AVG Volume (30 Days)
333.1K
2.2M
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$22,571,945.00
$127,626,000.00
Revenue This Year
$168.18
N/A
Revenue Next Year
$100.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
93.47
N/A
52 Week Low
$1.21
$0.99
52 Week High
$6.43
$3.60

Technical Indicators

Market Signals
Indicator
AMPG
MGNX
Relative Strength Index (RSI) 41.43 53.85
Support Level $2.76 $1.56
Resistance Level $3.14 $1.69
Average True Range (ATR) 0.21 0.10
MACD -0.02 0.02
Stochastic Oscillator 16.25 64.86

Price Performance

Historical Comparison
AMPG
MGNX

About AMPG Amplitech Group Inc.

AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: